Posted by Friends of FSH Research on Mar 6, 2021
Report by Dr. Statland
See also Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
The primary goal of our Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) study is to hasten therapeutic development for FSHD and improve care delivery by creating a standard clinic-based protocol informed by best practice guidelines to determine the predictive value of clinical characteristics and motor assessments on motor and health outcomes (i.e. need for orthotics, ambulation aides, respiratory support, etc.). The purpose of this study is to understand outcome assessments, define which assessments are meaningful to patients, and if certain values of outcome assessments help predict future motor or health outcomes of FSHD patients. MOVE FSHD is also unique in that it is truly meant to include all individuals with FSHD. Including those with FSHD type 2, children, those who are in a wheelchair, and women who are pregnant or wanting to become pregnant. MOVE FSHD would not be possible without the support of Friends of FSH Research, and studies like MOVE FSHD will help lay the groundwork to support future drug registration, and to refine FSHD care guidelines.
In our current study we have made considerable progress over the first 6 months. One of the most difficult parts of running a multicenter study is performing the ethical review, standardizing the documents and forms across all institutions, and training study personnel. We have completed training of 12 US academic institutions, including coordinators, evaluators, and principal investigators. We have completed ethical review at 7 US academic institutions, and completed the legal contracting and have activated 4 sites. We are pleased to announce we have enrolled our first 5 participants, and plan to have all 12 sites up and running by April 1st. This would be a big achievement for making the MOVE FSHD a reality, and the support from Friends of FSH Research has in a large part made this possible. The funding and activity to date have also attracted the notice of industry and other funders – and we are in the process of adding outcomes not funded directly in the current MOVE FSHD study, including MRI and additional biomarkers, which are essential to accelerate early phase drug development.